<DOC>
	<DOCNO>NCT02516813</DOCNO>
	<brief_summary>MSC2490484A M3814 investigational drug evaluate treatment subject locally advance tumor . The main purpose study determine safety , tolerability efficacy MSC2490484A combination radiotherapy combination chemoradiotherapy ( Radiotherapy + cisplatin ) .</brief_summary>
	<brief_title>Phase 1 Trial MSC2490484A , Inhibitor DNA-dependent Protein Kinase , Combination With Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Phase Ia part : advanced solid tumor metastases include lymphoma localize head neck region thorax indication fractionate palliative RT ( Arm A ) ; treatmentnaïve SCCHN eligible fractionate curatively intend RT concurrent cisplatin ( Arm B ) Phase Ib part : treatmentnaïve Stage III A/B NSCLC eligible surgical resection concurrent chemoradiation ( Arm A expansion cohort ) treatmentnaïve SCCHN eligible fractionate curatively intend RT concurrent cisplatin ( Arm B expansion cohort ) cPoP study : tumor least 2 ( sub ) cutaneous tumor/metastases least 2 cm apart RT naïve indication high dose palliative RT Availability archival tumor material , either block slide ( Phase Ia Ib ) . If archival material available fresh biopsy take Willing tumor biopsy collect cPoP Measurable evaluable disease RECIST v1.1 ( require cPoP study ) Eastern Cooperative Oncology Group performance status ( ECOG PS ) ≤ 2 Life expectancy ≥ 3 month ( Phase Ia , Arm A ) ≥ 6 month ( Phase Ia , Arm B Phase Ib ) Female subject childbearing potential male subject female partner childbearing potential must willing avoid pregnancy . Chemotherapy , immunotherapy , hormonal therapy , biologic therapy , anticancer therapy investigational medicinal product ( IMP ) within 28 day first trial drug intake Phase Ia subject , prior therapy Phase Ib subject . For subject rapidly grow tumor localize head neck region thorax treat physician wait 28 day , inclusion may take place residual toxicity previous treatment ( maximum CTCAE Grade 1 ) Prior RT region within 12 month ( Phase Ia , Arm A ; subject tumor localize head neck region thorax ) time previously ( Phase Ia , Arm B ; treatmentnaïve subject SCCHN Phase Ib ; treatmentnaïve subject Stage III A/B NSCLC SCCHN ) Extensive prior RT ≥30 % bone marrow reserve judge investigator prior bone marrow/stem cell transplantation within 5 year trial start . Poor vital organ function define : Bone marrow impairment evidence hemoglobin &lt; 10.0 g/dL , neutrophil count &lt; 1.0 × 109/L , platelet &lt; 100 × 109/L Renal impairment evidence serum creatinine &gt; 1.5 × upper limit normal ( ULN ) Liver function abnormality define total bilirubin &gt; 1.5 × ULN aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &gt; 2.5 × ULN ( except subject liver involvement , AST/ALT &gt; 5 × ULN ) Abnormality coagulation parameter . Received oral parenteral anticoagulant thrombolytic agent within 10 day first dose trial drug . Low dose high molecular weight heparin permit international normalized ratio within normal range History difficulty swallowing , malabsorption chronic gastrointestinal disease condition may hamper compliance and/or absorption IMP , use percutaneous endoscopic gastrostomy ( PEG ) tube Significant cardiac conduction abnormality , include history long QTc syndrome and/or pacemaker , impair cardiovascular function New York Heart Association classification score &gt; 2 . Subjects currently receive ( unable stop use prior receive first dose trial drug ) medication herbal supplement know potent inhibitor cytochrome P450 ( CYP ) 3A CYP2C19 ( must stop least 1 week prior ) , potent inducer CYP3A CYP2C19 ( must stop least 3 week prior ) , drug mainly metabolize CYP3A narrow therapeutic index ( must stop least one day prior ) . Subjects currently receive H2blocker proton pump inhibitor ( unable stop least 5 day prior first treatment ) . Main exclusion criterion cPoP History difficulty swallowing , malabsorption chronic gastrointestinal disease condition may hamper compliance and/or absorption IMP History significant medical disease major gastric small bowel surgery , recent drainage significant volume ascites pleural effusion ( per Investigator 's judgement ) psychiatric condition might impair subject 's wellbeing preclude full participation trial Subjects currently receive ( unable stop use prior receive first dose study drug ) medication herbal supplement know potent inhibitor CYP3A CYP2C19 must stop least 1 week prior take MSC2490484A . Subjects receive potent inducer CYP3A CYP2C19 must stop least 3 week prior take MSC2490484A . Those receive drug mainly metabolize CYP3A narrow therapeutic index judge Investigator ( optional consultation Sponsor ) must stop least one day prior take MSC2490484A .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>M3814</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>DNA-PK Inhibitor</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>